US Patent

US11110054 — Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate

Formulation · Assigned to Slayback Pharma LLC · Expires 2038-10-25 · 12y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable, ready-to-use injectable pharmaceutical compositions that combine neostigmine, glycopyrrolate, and a stabilizing agent in a liquid vehicle.

USPTO Abstract

The present invention provides stable, ready-to-use injectable pharmaceutical compositions, comprising the combination of neostigmine, glycopyrrolate, a stabilizing amount of one or more aminopolycarboxylic acids, and a pharmaceutically acceptable liquid vehicle. Other aspects of the invention relate to methods for making such compositions and methods of using such compositions for reversing the effects of non-depolarizing neuromuscular blocking agents. Preferably, the composition comprises neostigmine methylsulfate, glycopyrronium bromide, ethylenediaminetetraacetic acid (EDTA) and a pharmaceutically acceptable liquid vehicle, and is provided in a pre-filled, ready-to-use sealed container, such as a pre-filled syringe, suitable for intravenous administration.

Drugs covered by this patent

Patent Metadata

Patent number
US11110054
Jurisdiction
US
Classification
Formulation
Expires
2038-10-25
Drug substance claim
No
Drug product claim
Yes
Assignee
Slayback Pharma LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.